After the recent Advanced Therapies London conference by Terrapinn, Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, shared her perspective on key industry trends, particularly the evolving role of lentiviral vectors in advanced therapies.
A significant topic of discussion was the transition of lentiviral vectors from ex vivo applications to in vivo approaches, unlocking new possibilities for clinical trials and treatments. This transformation is being driven by advancements in vector engineering, targeting capabilities, and optimized manufacturing processes, paving the way for broader therapeutic applications.
Notably, the potential of lentiviral vectors was reinforced during the week of the congress when a major deal in in vivo lentiviral vector technology was closed between a European biotech and a leading pharmaceutical company.
At VIVEbiotech, we have a proven track record in developing and manufacturing lentiviral vectors for in vivo administration, supporting cutting-edge advanced therapy programs worldwide.
Natalia’s expert insights were recently featured in Drug Discovery World, where she highlighted how lentiviral vectors are playing a crucial role in advanced therapies for rare diseases and oncology, among other indications.
Read the full article here: https://www.ddw-online.com/industry-insight-from-spring-2025-events-34226-202503/